Beste apotheek van Nederland

Topical Treatments ....................................................................................................................... 88
Hormonal Treatments ................................................................................................................... 91
Other Treatments (Off Label) ..................................................................................................... 100
Question 3a. What are the Harms of Pharmaceutical Treatments for Male Patients With ED?. 103
Oral Medications: PDE–5 Inhibitors .......................................................................................... 103
Injection Treatments ................................................................................................................... 103
Chapter 4. Discussion ................................................................................................................. 105
Strength of the Evidence............................................................................................................. 105
Question 1: What is the Clinical Utility of Routine Blood Tests—Testosterone, Prolactin,
Luteinizing Hormone, Follicle-stimulating Hormone—in Identifying and Affecting Therapeutic
Outcomes for Treatable Causes of ED?...................................................................................... 107
Questions 2–3: What Are the Benefits and Harms of Pharmaceutical Treatments for ED? ..... 109
Question 2a-b: Do Specific Patient Characteristics (e.g. Origin, Severity, or Duration of ED,
and Comorbid Conditions) Affect Prognosis or Treatment Success for ED patients?............... 117
Questions 3a: Specific Harms of Pharmaceutical Treatments in Male Patients with ED .......... 118
Methodological and Logistic Limitations of the Systematic Review......................................... 119
Future Research Recommendations............................................................................................ 120
Tables
Table 1: Population Characteristics of Studies Measuring Hypogonadism in Men with Erectile
Dysfunction…………………………………………………………………………………..…121
Table 2: Prevalence of Hypogonadism in Men With Erectile Dysfunction (Serum Total
Testosterone………………………………………………………………………………….....125
Table 3: Prevalence of Hypogonadism in Men With Erectile Dysfunction (Serum Free or
Calculated Testosteron…………………………………………………………………………128
Table 4: Prevalence of Hypogonadism in Men With Erectile Dysfunction (Serum Bioavailable
Testosterone…………………………………………………………………………………….129
Table 5: Population Characteristics of Studies Measuring Hyperprolactinemia in Men with
Erectile Dysfunction……………………………………………………………………………129
Table 6: Prevalence of Hyperprolactinemia in Men With Erectile Dysfunction (Serum Prolactin
Levels…………………………………………………………………………………………...131
Table 7: Prevalence of Hyperprolactinemia in Men With and Without Erectile Dysfunction
(Serum Prolactin Levels)………………………………………………………………………133
Table 8: Population Characteristics of Studies Measuring Serum LH/FSH Levels in Men With
Erectile Dysfunction……………………………………………………………………………133
Table 9: Prevalence of Primary or Secondary Hypogonadism in Men With Erectile Dysfunction
(Total Serum Levels of LH and FSH) ………………………………………………………….135
Table 10: Serious Adverse Events in Sidenafil vs. Placebo (Data From RCTs) ………………137
Table 11: Efficacy Results of Tadalafil by ED Severity Groups……………………………….139
Table 12: Intracavernosal Injection: Sexual Intercourse Success………………………………140
Table 13: Intracavernosal Injection: Improvement in Erections ………………………………140
Table 14: Intracavernosal Injection: Patients With Adverse Events……………………………145
Table 15: Subcutaneous Injection: Improvement in Erections…………………………………150
Table 16: Subcutaneous Injection: Patients With Adverse Events……………………………...151
viii